Palisade Bio to Participate in the Virtual Investor Lunch Break Event
April 11, 2024 09:15 ET
|
Palisade Bio, Inc.
– Live webcast with members of Palisade Bio management on Tuesday, April 16th at 12:00 PM ET Carlsbad, CA, April 11, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”,...
Palisade Bio Presents Development Overview of PALI-2108 at the IBD Innovate: Product Development for Crohn’s & Colitis™
April 10, 2024 08:15 ET
|
Palisade Bio, Inc.
– PALI-2108 in development for the treatment of moderate-to-severe ulcerative colitis (UC) advancing towards Phase 1 clinical study before year end Carlsbad, CA, April 10, 2024 (GLOBE...
Palisade Bio Announces 1-for-15 Reverse Stock Split
April 03, 2024 17:30 ET
|
Palisade Bio, Inc.
Carlsbad, CA, April 03, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), (“Palisade”, “Palisade Bio” or the “Company”), a biopharmaceutical company focused on developing and...
Palisade Bio Reports Year End 2023 Financial Results and Provides Corporate Update
March 27, 2024 08:00 ET
|
Palisade Bio, Inc.
– Rapid advancement of PALI-2108 towards Phase 1 clinical study for the treatment of moderate-to-severe ulcerative colitis; On track to commence Phase 1 before year end – Formation of Clinical...
Palisade Bio to Present at Digestive Disease Week (DDW) 2024
February 15, 2024 08:35 ET
|
Palisade Bio, Inc.
Carlsbad, CA, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a biopharmaceutical company focused on developing novel therapeutics for serious...
Palisade Bio Provides Corporate Update and Reiterates Guidance
February 13, 2024 08:35 ET
|
Palisade Bio, Inc.
– Company announces strategic streamlining of Board to align with the current state of clinical development and corporate vision – Advancement of PALI-2108 for the treatment of moderate-to-severe...
Correction Notice of Palisade Bio’s Press Release Announcing the Appointment of Clinical Advisory Board Members
February 08, 2024 14:40 ET
|
Palisade Bio, Inc.
Carlsbad, CA, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a biopharmaceutical company focused on developing novel therapeutics for...
Palisade Bio Announces Formation of Clinical Advisory Board with Appointments of Preeminent Key Opinion Leaders
February 08, 2024 08:05 ET
|
Palisade Bio, Inc.
Bruce Sands, MD, MS., Dr. Burrill B. Crohn Professor of Medicine, Icahn School of Medicine at Mount Sinai and System Chief, Division of Gastroenterology, Mount Sinai Health SystemFlorian Rieder, MD,...
Palisade Bio Announces Exercise of Previously Issued Warrants for $2.5 Million
January 30, 2024 09:25 ET
|
Palisade Bio, Inc.
Carlsbad, CA, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a biopharmaceutical company focused on developing novel therapeutics for...
Palisade Bio Announces Positive Preclinical Data of Lead Program PALI-2108 at the 2024 Crohn’s & Colitis Congress
January 29, 2024 08:05 ET
|
Palisade Bio, Inc.
– Preclinical data demonstrated PALI-2108 to be safe and well tolerated – PALI-2108 is orally delivered and colon activated allowing for local activity with low systemic exposure – Company...